Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ARGSQ OTCMKTS:BCTXF NASDAQ:BPTSY OTCMKTS:OMGAQ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARGSQArgos Therapeutics$0.05$0.05$0.02▼$0.25$572K2.4713,394 shsN/ABCTXFBriaCell Therapeutics$0.72+4.5%$2.10$3.25▼$17.50$556K1.091,859 shs476,910 shsBPTSYBiophytis$1.81$1.58$1.33▼$7.48$634K0.811,745 shsN/AOMGAQOmega Therapeutics$0.00$0.08$0.00▼$1.69$166K0.57215,590 shsN/AReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARGSQArgos Therapeutics0.00%0.00%0.00%0.00%0.00%BCTXFBriaCell Therapeutics+0.78%-3.17%-64.34%-75.99%+18.60%BPTSYBiophytis0.00%0.00%+35.71%-13.22%-70.41%OMGAQOmega Therapeutics0.00%+275.00%-95.32%-97.60%-99.80%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARGSQArgos TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ABCTXFBriaCell TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ABPTSYBiophytisN/AN/AN/AN/AN/AN/AN/AN/AOMGAQOmega Therapeutics2.6836 of 5 stars3.34.00.00.00.61.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARGSQArgos Therapeutics 0.00N/AN/AN/ABCTXFBriaCell Therapeutics 0.00N/AN/AN/ABPTSYBiophytis 0.00N/AN/AN/AOMGAQOmega Therapeutics 2.67Moderate Buy$8.00266,566.67% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARGSQArgos Therapeutics$1.90M0.30N/AN/A($1.63) per share-0.03BCTXFBriaCell TherapeuticsN/AN/AN/AN/A($4.55) per shareN/ABPTSYBiophytisN/AN/AN/AN/A($16.18) per shareN/AOMGAQOmega Therapeutics$3.09M0.05N/AN/A$1.05 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARGSQArgos Therapeutics-$40.57MN/A0.00∞N/AN/AN/AN/AN/ABCTXFBriaCell Therapeutics-$3.68M-$3.84N/A∞N/AN/AN/A-786.77%N/ABPTSYBiophytis-$18.43MN/A0.00∞N/AN/AN/AN/AN/AOMGAQOmega Therapeutics-$97.43M-$1.33N/AN/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARGSQArgos TherapeuticsN/AN/AN/AN/AN/ABCTXFBriaCell TherapeuticsN/AN/AN/AN/AN/ABPTSYBiophytisN/AN/AN/AN/AN/AOMGAQOmega TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARGSQArgos TherapeuticsN/AN/AN/ABCTXFBriaCell TherapeuticsN/A0.070.07BPTSYBiophytisN/A0.41N/AOMGAQOmega TherapeuticsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARGSQArgos TherapeuticsN/ABCTXFBriaCell TherapeuticsN/ABPTSYBiophytis0.05%OMGAQOmega Therapeutics97.47%Insider OwnershipCompanyInsider OwnershipARGSQArgos Therapeutics28.21%BCTXFBriaCell TherapeuticsN/ABPTSYBiophytis3.70%OMGAQOmega Therapeutics8.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARGSQArgos Therapeutics12210.59 millionN/ANot OptionableBCTXFBriaCell Therapeutics8772,000N/ANot OptionableBPTSYBiophytis30351,000338,000N/AOMGAQOmega Therapeutics12055.37 million50.66 millionOptionableOMGAQ, BPTSY, ARGSQ, and BCTXF HeadlinesRecent News About These CompaniesOMGAQ - Omega Therapeutics Inc Executives | MorningstarAugust 5, 2025 | morningstar.comMOmega Therapeutics Inc (OMGAQ)March 5, 2025 | investing.comHuge distressed drugmaker seeks sale in Chapter 11 bankruptcyFebruary 27, 2025 | msn.comIntrommune Therapeutics Announces Publication of OMEGA Study in Peanut Allergic Adults in Annals of Allergy, Asthma & ImmunologyFebruary 19, 2025 | markets.businessinsider.comOmega Therapeutics secures $9.8M in DIP financingFebruary 14, 2025 | msn.comOmega Therapeutics Hits Chapter 11February 10, 2025 | usaherald.comUFlagship’s Omega Thera to file for bankruptcyFebruary 5, 2025 | thepharmaletter.comTFlagship-backed Omega signals it’s headed toward bankruptcyFebruary 5, 2025 | biopharmadive.comBThe OMGA Conundrum: Why Omega Therapeutics Inc’s Stock Is Making Headlines AgainFebruary 5, 2025 | bovnews.comBNovo Partner Omega Waves Bankruptcy Flag from Sinking ShipFebruary 4, 2025 | biospace.comBFlagship spinout Omega is days away from bankruptcy, it says in filingFebruary 4, 2025 | endpts.comEWhat’s Behind the 11.36% Gain in Omega Therapeutics Inc (OMGA) Stock? Find Out Now!January 30, 2025 | bovnews.comBOmega Therapeutics announces board reshuffle and new directorJanuary 29, 2025 | msn.comFlagship Pioneering partners with Cambridge, UK institutionsJanuary 25, 2025 | thepharmaletter.comTOmega Therapeutics stock hits 52-week low at $0.52January 21, 2025 | msn.comOmega Therapeutics Appoints New Director Ravi MehrotraDecember 6, 2024 | tipranks.comOmega Pacific Reports Its Final Drill Hole Yielding Multiple Zones of Mineralization at Its Williams PropertyDecember 4, 2024 | accesswire.comAOmega Pacific Announces 2024 Work Program Results From Its Lekcin PropertyNovember 19, 2024 | accesswire.comAOmega Therapeutics Reports Third Quarter 2024 ResultsNovember 19, 2024 | markets.businessinsider.comOmega Therapeutics price target lowered to $4 from $9 at Piper SandlerNovember 16, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOMGAQ, BPTSY, ARGSQ, and BCTXF Company DescriptionsArgos Therapeutics OTCMKTS:ARGSQ$0.05 0.00 (0.00%) As of 10/10/2019Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina. On November 30, 2018, Argos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware.BriaCell Therapeutics OTCMKTS:BCTXF$0.72 +0.03 (+4.53%) As of 08/12/2025BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.Biophytis NASDAQ:BPTSY$1.80 0.00 (0.00%) As of 08/13/2025Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.Omega Therapeutics OTCMKTS:OMGAQ$0.0030 0.00 (0.00%) As of 08/11/2025Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore Brinker Serves Up Earnings Beat, Sidesteps Cost Pressures CAVA’s Honeymoon Ends With a 16% Stock Drop Rigetti Stock: A Long-Term Quantum Play Facing Short-Term Tests 5 Stocks Insiders Are Selling That Analysts Say Buy CoreWeave Pulls Back Into a Screaming Buy Amazon’s Bears Have Raised the White Flag—Get Excited Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access